Aquestive targets Q3 NDA resubmission for Anaphylm while maintaining 2026 revenue guidance of $46M-$50M (NASDAQ:AQST)
· seekingalpha.com
AQST Q2 2026 earnings call highlights: Anaphylm NDA resubmission timeline, FDA review risks, HF/PK data, refinancing and guidance—read key insights.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...